Navigation Links
Cytopia Appoints Study Chairman for JAK2 Clinical Trial
Date:7/29/2008

MELBOURNE, Australia, July 29 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) has appointed Dr. Ayalew Tefferi, Professor of Medicine and Hematology at the Mayo Clinic College of Medicine, as Clinical Study Chair for the company's Phase I/II study in patients with myelofibrosis.

Dr. Tefferi is a world-renowned expert in the treatment of myeloproliferative disorders (MPDs) and has authored over 500 research publications and given many hundreds of invited lectures in haematology. He also serves on the editorial boards of a number of leading haematology journals.

Myelofibrosis patients suffer a bone marrow disorder in which the marrow is replaced by fibrous scar tissue. Patients will be treated in this study with Cytopia's novel orally available compound CYT387. This drug inhibits the mutant JAK2 enzyme to specifically treat haematological malignancies, including myelofibrosis.

Many of these particular diseases can lead to life threatening conditions such as leukemia. There are currently no effective long term treatments for these conditions.

"Cytopia is delighted that a clinician of Dr. Tefferi's standing has agreed to chair our Phase I/II program," said Mr. Andrew Macdonald, CEO. "Dr. Tefferi and our other clinical investigators will study and document the clinical benefits of using this highly promising JAK2 inhibitor to treat these blood disorders."

Following the completion of very encouraging in-vivo studies at Oregon Health and Science University early in the year, CYT387 has been undergoing rigorous IND-enabling toxicology studies in recent months. It is anticipated that an Investigational New Drug application will be lodged with the US Food and Drug Administration by the end of the year to support studies in Australia and the United States.

About JAK2

The discovery of a specific single activating mutation in the JAK2 enzyme in MPDs in 2005 has focused attention on developing a therapy for these diseas
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
2. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
3. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. West Pharmaceutical Services, Inc. Appoints New Director
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Curemark Appoints Preeminent Pediatrics Gastroenterologist
8. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
9. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... DIEGO, Calif. and RESEARCH TRIANGLE PARK, N.C. ... (Nasdaq: OREX ), a biopharmaceutical company focused on ... a global provider of drug development and manufacturing services, ... Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as ...
... Inc. (Headquarters: Woodcliff Lake, New Jersey , Chairman and CEO: Hajime Shimizu , "Eisai") today announces ... (Headquarters: Baltimore, Maryland , Director: John Griffin , M.D., "BSI") related to Eisai,s GCPII (glutamate carboxypeptidase ... ... , ...
Cached Medicine Technology:Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 2Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 3Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 4Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 5Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 2Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 3
(Date:4/17/2014)... 17, 2014U.S. military personnel who served in Iraq ... traumatic brain injury (TBI) were compared to military ... medical reasons. Differences in measures of overall disability, ... after injury are reported in an article in ... from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... School of Medicine (BUSM) have discovered that the ... experimental model. The findings, reported in the ... may lead to more effective treatments for alcoholism. ... the leading causes of illness and death in ... by limiting the productivity of workers and necessitating ...
(Date:4/17/2014)... (SACRAMENTO, Calif.) An international team led by researchers ... protein complex, which plays a key role in cell ... process. This is the first time the complex has ... could make cyclin B1/Cdk1 an excellent target to control ... medicine. The research was published online today in the ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... Earns 510(k) Clearance for AutoLITT(TM)KALAMAZOO, Mich., and WINNIPEG, Manitoba, ... investigational use at both The Cleveland Clinic and University ... brain tumor patients and has earned clearance from the ... The first applications of the technology are expected ...
... for all health data processing and transactionsPARSIPPANY, ... healthcare EDI company that processes insurance transactions ... has achieved full accreditation with the Healthcare ... Healthcare Network Accreditation Commission (EHNAC). EHNAC,s HNAP ...
... nonprofit leader in ending homelessness at its roots, today ... Council, a group of some of the nation,s leading ... Council members, many of whom are veterans themselves, will ... experience to enable Jericho to serve veterans from all ...
... IBM (NYSE: IBM ) today announced that ... Excellence located in La Gaude, France. (Logo: ... global healthcare capability, the Centre of Excellence will help ... sciences solutions that improve care delivery, predict and prevent ...
... Medical Center-University surveyCHARLOTTE, N.C., May 13 Dr. ... a top score for plastic surgery in the ... a tremendous honor for Dr. Capizzi and his ... coordinates the program and selects the honorees. "The ...
... In U.S., 40 percent of new moms aren,t married, CDC ... The number of unmarried women having children has risen sharply ... U.S. health officials. , In the United States, 40 percent ... these are to women in their 20s, not teenagers, according ...
Cached Medicine News:Health News:Treating Untreatable Brain Tumors: FDA Approves New Laser Surgery 2Health News:MD On-Line, Inc. Receives EHNAC Healthcare Network Accreditation 2Health News:MD On-Line, Inc. Receives EHNAC Healthcare Network Accreditation 3Health News:Jericho Project Creates Veterans Advisory Council 2Health News:Jericho Project Creates Veterans Advisory Council 3Health News:Jericho Project Creates Veterans Advisory Council 4Health News:IBM Establishes Global Healthcare Centre of Excellence in La Gaude, France 2Health News:IBM Establishes Global Healthcare Centre of Excellence in La Gaude, France 3Health News:Dr. Peter J. Capizzi of Stillwater Plastic Surgery Honored in Patient Satisfaction Survey 2Health News:More Single Women Are Having Babies 2Health News:More Single Women Are Having Babies 3Health News:More Single Women Are Having Babies 4
... Retractor System represents the most widely ... Its wide array of retraction components ... versatile system for multi-directional exposure of ... are available for specific procedures: IMA ...
Rainbow technology combines the latest in system theory, adaptive signal processing and a revolutionary sensor that employs eight wavelengths of light to collect and analyze an extraordinarily rich s...
... real-time PCR analysis of gene expression ... LightCycler 480 System combines amazing speed ... the needs of a broad range ... including array validation, gene-knockdown studies, and ...
... PyGON now offers a very unique product series, ... alarm dialing for refrigerators and freezers. This is ... only a phone line. With our VM500 solution ... to 128 points over one phone line. The ...
Medicine Products: